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ARTICLE
Fine Mapping Seronegative and Seropositive
Rheumatoid Arthritis to Shared and Distinct HLA Alleles
by Adjusting for the Effects of Heterogeneity
Buhm Han,1,2,3 Dorothée Diogo,1,2,3,4 Steve Eyre,5,6 Henrik Kallberg,7 Alexandra Zhernakova,8,9
John Bowes,5,6 Leonid Padyukov,7 Yukinori Okada,1,2,3,4 Miguel A. González-Gay,10
Solbritt Rantapää-Dahlqvist,11 Javier Martin,12 Tom W.J. Huizinga,8 Robert M. Plenge,13
Jane Worthington,5,6 Peter K. Gregersen,14 Lars Klareskog,7 Paul I.W. de Bakker,1,2,15
and Soumya Raychaudhuri1,2,3,4,5,*
Despite progress in defining human leukocyte antigen (HLA) alleles for anti-citrullinated-protein-autoantibody-positive (ACPAþ) rheumatoid arthritis (RA), identifying HLA alleles for ACPA-negative (ACPA) RA has been challenging because of clinical heterogeneity
within clinical cohorts. We imputed 8,961 classical HLA alleles, amino acids, and SNPs from Immunochip data in a discovery set
of 2,406 ACPA RA case and 13,930 control individuals. We developed a statistical approach to identify and adjust for clinical heterogeneity within ACPA RA and observed independent associations for serine and leucine at position 11 in HLA-DRb1 (p ¼ 1.4 3 1013,
odds ratio [OR] ¼ 1.30) and for aspartate at position 9 in HLA-B (p ¼ 2.7 3 1012, OR ¼ 1.39) within the peptide binding grooves.
These amino acid positions induced associations at HLA-DRB1*03 (encoding serine at 11) and HLA-B*08 (encoding aspartate at 9).
We validated these findings in an independent set of 427 ACPA case subjects, carefully phenotyped with a highly sensitive ACPA
assay, and 1,691 control subjects (HLA-DRb1 Ser11þLeu11: p ¼ 5.8 3 104, OR ¼ 1.28; HLA-B Asp9: p ¼ 2.6 3 103, OR ¼ 1.34).
Although both amino acid sites drove risk of ACPAþ and ACPA disease, the effects of individual residues at HLA-DRb1 position 11
were distinct (p < 2.9 3 10107). We also identified an association with ACPAþ RA at HLA-A position 77 (p ¼ 2.7 3 108,
OR ¼ 0.85) in 7,279 ACPAþ RA case and 15,870 control subjects. These results contribute to mounting evidence that ACPAþ and
ACPA RA are genetically distinct and potentially have separate autoantigens contributing to pathogenesis. We expect that our
approach might have broad applications in analyzing clinical conditions with heterogeneity at both major histocompatibility complex
(MHC) and non-MHC regions.

Introduction
Rheumatoid arthritis (RA [MIM 180300]) has two distinct subtypes—anti-citrullinated-protein-autoantibodynegative (ACPA or seronegative) RA and -positive
(ACPAþ or seropositive) RA—with potentially different genetic risk factors, environmental risk factors, and optimal
therapeutic strategies.1,2 Despite constituting about onethird (~30%) of RA cases,3 ACPA RA has been relatively
understudied in comparison to ACPAþ RA.4–7 We and
others have demonstrated that the widely established
method for identifying ACPA RA subjects on the basis
of anticyclic citrullinated peptide (anti-CCP) antibody
testing is imperfect in that the absence of antibody is not
sufficiently specific to ACPA RA, whereas its presence is
specific to ACPAþ RA.8–10

The lack of a specific test for ACPA RA can result in heterogeneity in clinical cohorts, which can confound genetic
studies for ACPA disease. For example, ACPA RA subjects
might include ACPAþ RA subjects whose ACPAs have not
been detected by conventional anti-CCP testing8–11 or subjects who have other autoantibody-negative inflammatory
arthritic conditions, such as ankylosing spondylitis (AS)12
or other HLA-B*27-associated conditions. So, although investigators have reported associations between classical
HLA alleles and ACPA RA,13,14 it remains unclear whether
these associations are distinct from those alleles driving
ACPAþ disease risk, recently defined by our group.6 Additionally, the specific amino acid sites and residues driving
ACPA RA risk have yet to be defined.
To define HLA alleles driving ACPA RA risk, we first
obtained dense SNP genotype data within the major
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histocompatibility complex (MHC) region by applying
the Immunochip custom array3 to ACPA case and control groups. We then used these data to impute HLA
alleles, amino acids, and SNPs with a highly accurate
imputation approach.15 Recognizing that possible clinical
heterogeneity within genotyped cohorts might confound
associations within the MHC, we developed a statistical
approach to correct for the effects of heterogeneity
within cohorts; it uses genetic risk scores (GRSs) built
from known risk loci for potential confounding diseases
as covariates.
We observed that two amino acid positions, HLA-DRb1
position 11 (in which serine and leucine conferred risk)
and HLA-B position 9 (in which aspartate conferred risk),
were driving ACPA RA. These two positions are already
known to drive ACPAþ RA as well;6 however, the specific
amino acid residues conferring risk were completely
distinct between the two disease subtypes. We also separately tested for associations with ACPAþ disease. In addition to confirming known associations at positions 11,
71, and 74 in HLA-DRb1, position 9 in HLA-B, and position
9 in HLA-DPb1, we identified an additional association
at amino acid position 77 within the binding groove of
HLA-A. These results contribute to mounting evidence
that ACPAþ and ACPA RA are distinct diseases with
certain unique genetic factors.

Material and Methods
Samples
Case-Control Sample Collections
We used data from six case-control collections (UK, US, Dutch,
Spanish, Swedish Umeå, and Swedish Epidemiological Investigation of Rheumatoid Arthritis [EIRA], Table S1, available online).3
All individuals provided informed consent and were recruited
through protocols approved by institutional review boards. Each
collection consisted of individuals who were self-described as
white and of European descent, and all cases either met the
1987 American College of Rheumatology diagnostic criteria or
were diagnosed by board-certified rheumatologists. We previously
genotyped all samples with the Immunochip custom array, which
densely covered the MHC region (7,563 SNPs), in accordance with
Illumina protocols.
Classifying ACPA RA in Discovery Samples
From these samples, we defined a total of 2,406 ACPA RA case
and 13,930 control subjects for discovery from five collections
(excluding the Swedish EIRA). To do this, we followed standard
clinical practice to identify ACPA RA subjects as those who
were not reactive to anti-CCP antibody by using reference
cutoff levels defined at local clinical labs. In the UK cohort, we
used the commercially available DiastatTM ACPA Kit (AxisShield Diagnostics Limited). In the US samples, we used a second-generation commercial anti-CCP enzyme immunoassay
(Inova Diagnostics).16 For Spanish samples, we used the Immunoscan ELISA test (Euro Diagnostica). For the Swedish Umeå and
Dutch collections, we used the Immunoscan-RA Mark2 ELISA
test (Euro Diagnostica).17 These assays are the standard commercially available assays that are currently being widely used in
clinical practice.

Clinically Homogeneous ACPA Samples for Replication
To replicate ACPA results, we sought to define an independent
replication data set that was as clinically homogeneous as possible.
To this end, we used genotype data on 987 case and 1,940 control
subjects who were from the Swedish EIRA cohort and who were
identified as anti-CCP antibody negative with the ImmunoscanRA Mark2 ELISA test (Euro-Diagnostica). In addition, to stringently
ensure clinical homogeneity, we applied a highly sensitive ACPA
typing method developed at the Karolinska Institutet8 to test sera
for reactivity to four specific citrullinated peptides (a-enolase, vimentin, fibrinogen, collagen type II). We considered samples
ACPA only if they were negative for all four of these tests. After
applying this assay, we removed 106 case individuals who were reactive to the sensitive assay, as well as 381 case individuals to whom
we did not apply the assay. We also excluded 73 case and 249 control
subjects who were positive for HLA-B*27. Because HLA-B*27 is
highly sensitive for AS (>90%), excluding HLA-B*27-positive individuals effectively removed the effect of possible confounding
from AS or related spondyloarthropathies. The resulting replication
collection consisted of 427 case and 1,691 control subjects.
Sample Collections for ACPAþ RA
For ACPAþ RA, we used 7,279 anti-CCP-positive individuals from
all six cohorts (UK, US, Swedish Umeå, Dutch, Spanish, and
Swedish EIRA; Table S1). We used all 15,870 control subjects for
ACPAþ RA analyses.

Statistical Analyses
HLA Imputation
We imputed case and control groups together for 8,961 binary
markers representing classical HLA alleles, amino acids, and
SNPs by using SNP2HLA,15 which utilizes the Beagle imputation
method.18 The binary markers included every possible grouping
of amino acid residues given a multiallelic amino acid position.
We used reference data collected by the Type 1 Diabetes Genetics
Consortium;19 these data consisted of genotypes for 5,863
SNPs tagging the MHC and classical alleles for HLA-A, HLA-B,
HLA-C, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1, and
HLA-DPB1 at four-digit resolution in 5,225 individuals of European descent.19
Quantifying Imputation Accuracy
To assess accuracy, we took advantage of typed HLA-A, HLA-B,
HLA-C, HLA-DQB1, and HLA-DRB1 alleles for 918 individuals in
the UK cohort. We calculated imputation accuracy as the proportion of correctly imputed classical alleles:
P

 


 



d gi;1 ¼ xi;1 þ d gi;2 ¼ xi;2 ; d gi;1 ¼ xi;2 þ d gi;2 ¼ xi;1
;
2n

i max

where gi;1 and gi;2 are genotyped alleles of individual i and xi,1 and
xi,2 are imputed alleles. For each gene, we used individuals successfully typed for four-digit alleles. The d function is 1 if the genotyped allele is the imputed allele and 0 otherwise. The term n is
the number of samples.
Statistical Framework for Association Testing
We tested associations at all 8,961 binary markers by using probabilistic genotypic dosages that take uncertainty in imputation into
account. We used logistic regression under the assumption that
each marker conferred a fixed log additive effect across each
case-control collection. To account for population stratification,
we included ten principal components (PCs) as covariates for
each collection. We calculated PCs by using EIGENSOFT v.4.220
with HapMap Phase 2 samples as reference populations on a

The American Journal of Human Genetics 94, 522–532, April 3, 2014 523

subset of SNPs (minor allele frequency > 0.05) filtered for minimizing intermarker linkage disequilibrium (LD).3 This resulted in
the following logistic regression model:


X
X
d
p
logðoddsi Þ ¼ q þ ba ga;i þ
i;j gj þ
j;k pi;k ;
j˛collections
k¼1:::10
(Equation 1)
where a indicates the marker being tested, ga;i is the dosage of a in
individual i, and ba is the additive effect of a. In the collection-specific term, di,j is an indicator variable that is 1 only if individual i is
in collection j. The gj parameter is the collection-specific effect due
to the differences in case-control proportions; it is set to 0 for one
arbitrarily selected reference collection. The pj,k parameter is the
effect of the kth PC, and pi,k is the kth PC value for individual i.
Adjusting for Clinical Heterogeneity in ACPA Discovery
In the discovery analysis for ACPA disease, we adjusted for
possible clinical heterogeneity within the collections. Our
approach was to extend Equation 1 to include GRSs of potentially
confounding diseases as covariates:
logðoddsi Þ ¼ q þ ba ga;i þ

X
j˛Collections


X
di;j gi þ
pj;k pi;k
k¼1:::10

X
þ
aj;h si;h ;
h¼1:::H
(Equation 2)

where h indicates a confounding disease we want to adjust for and
H is the total number of confounding diseases. si,h is the GRS of individual i for disease h and is defined as the sum of risk-allele dosages weighted by effect sizes:
X
si;h ¼
b gl;i ;
(Equation 3)
l l;h
where l iterates over known risk alleles for h, bl;h is the effect size of
l for h, and gl;i is the dosage of l in individual i. aj,h is the effect of
si,h, which approximates the sample proportion of confounding
disease in the collection. For a detailed description of the method,
see Appendix A.
For our analysis, we adjusted for both ACPAþ RA and AS. For the
ACPAþ RA GRS, l iterated over 47 independent SNPs associated
with ACPAþ RA (Table S2),3 all four-digit HLA-DRB1 alleles,
HLA-B Asp9, HLA-DPb1 Phe9, and HLA-A Asn77. We estimated
bl from our ACPAþ RA case-control data set presented in this paper.
To estimate bl for all four-digit HLA-DRB1 alleles in a multivariate
model, we included in the logistic regression all four-digit alleles
with allele frequency > 0.1%, except for the reference allele we
chose (HLA-DRB1*15:01). To avoid reusing the same controls
both to estimate bl and to map ACPA RA, which could result in
bias as a result of overfitting, we estimated bl for each collection
by using the other five collections. Similarly, for the AS GRS, l iterated over HLA-B*27 and 19 AS-associated SNPs that passed our
quality control (QC) (Table S2).12 We used reported effect sizes bl
in Cortes et al.12
Two-Step Approach for Adjusting for Heterogeneity
Using GRSs as covariates in regression might be overly conservative and could remove true associations if the causal loci are shared
between the disease of interest and the confounding disease. To
account for the shared genetic structure between the two RA subtypes, we employed an alternative two-step approach: (1) we estimated the confounding proportions aj,h in Equation 2 by using
GRSs based on nonshared loci first, which gave us an unbiased
estimate of aj,h, and then (2) we used this aj,h as a fixed value in
the regression framework presented above. Because we did not
definitively know which loci were shared, we used a heuristic to

choose nonshared loci by using 38 non-MHC SNPs not associated
with ACPA RA at a nominal significance threshold (p > 0.01)3
(Table S2).
Genomic-Control Inflation Factor
We assessed the genomic-control inflation factor, lGC, by testing
associations at ‘‘reading-writing-ability SNPs’’ included on the
Immunochip platform. Out of 1,469 SNPs, we used 1,250 that
passed QC in all six collections. We obtained chi-square statistics
at these SNPs by using logistic regression as described above to
assess lGC.
Forward Conditional Search
Once we identified an associated marker, we forward searched
further associations by including the identified marker as a covariate in the logistic regression.
Exhaustive Search
To find the best pair of associations in HLA-DRB1 and HLA-B for
ACPA disease, we examined every possible combination of 495
binary markers within HLA-DRB1 and 774 binary markers within
HLA-B (383,130 tests). We extend the single-marker model in
Equation 2 to the following two-marker model:
logðoddsi Þ ¼ q þ ba ga;i þ bb gb;i

X
X
þ
di;j gi þ
pj;k pi;k (Equation 4)
j˛collections
k¼1.10

X
þ
a
j;h si;h ;
h¼1.H
where a and b are the pair of binary markers being tested.
We calculated the log-likelihood difference (DLL) in model fit
due to this pair and assessed significance by comparing the deviance (2 3 DLL) to a chi-square distribution with 2 degrees of
freedom.
Joint Analysis of Discovery and Replication Data
In order to jointly analyze five discovery collections and a replication cohort for ACPA disease, we combined them into one logistic regression framework, including GRSs as covariates for five
discovery cohorts to adjust for heterogeneity.
Forward Search outside of HLA-DRB1 for ACPAþ RA
Because HLA-DRB1 has a very strong effect in ACPAþ disease,
to examine the associations beyond HLA-DRB1, we conditioned
on the HLA-DRB1 effects by including binary variables as
covariates corresponding to all four-digit HLA-DRB1 alleles,
excluding one allele as a reference (HLA-DRB1*15:01). If we forward searched by conditioning on an amino acid position with
m residues, such as position 9 of HLA-B, we included binary variables corresponding to the m  1 residues, excluding the most
frequent one.
Testing for Discordant Effect Sizes
Given a multiallelic amino acid position with m residues, we
wanted to test whether the effect sizes of m residues were concordant between two different conditions (e.g., ACPA versus
ACPAþ). To this end, we calculated multivariate odds ratios
(ORs) of residues by including in the logistic regression m  1
binary markers corresponding to m  1 residues, excluding one
residue as the reference. Let a1, ., am  1 and b1, ., bm  1 be
the multivariate log ORs in two different conditions. Let v1, .,
vm  1 and u1, .,um  1 be their variances. To test discordance of
effect sizes between two conditions, we used the statistic
X
i¼1.m

ðai  bi Þ2
;
vi þ ui

(Equation 5)

which is chi-square distributed with m  1 degrees of freedom
under the null.
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Assessing Accuracy of Fine Mapping with Simulations
To test the accuracy of our approach to adjust for clinical heterogeneity in fine mapping, we simulated an ACPA RA case-control
study confounded by ACPAþ RA. We simulated a large study
(50,000 case and 50,000 control subjects) to assess the asymptotic
results. We first simulated control subjects by sampling with
replacement from the UK control subjects. Then we assumed
that specific amino acid positions were conferring risk to ACPA
RA with predefined ORs, and we sampled ACPA RA subjects
from the UK control subjects on the basis of the ORs. Finally, we
replaced 26.3% of the case group with individuals randomly
sampled from the UK ACPAþ RA case group. We performed an
association test with and without adjusting for heterogeneity to
examine whether we could fine map the risk-conferring amino
acid positions correctly. To adjust for heterogeneity, we used
GRSs built from the effect sizes estimated from the other five
cohorts, excluding the UK cohort.

Results
ACPA RA Discovery Collection and HLA Imputation
To define HLA alleles driving ACPA RA risk, we analyzed a
discovery data set of 2,406 ACPA RA case and 13,930 control subjects (from the UK, the US, Spain, Sweden, and the
Netherlands, see Table S1) genotyped on the Immunochip
custom array with 7,563 SNPs across the MHC region.3
This platform represents greater SNP density than most
standard genome-wide-association-study arrays and offers
the potential for higher HLA imputation accuracy. Indeed,
applying SNP2HLA,15 we observed an overall imputation
accuracy of 96.9% for four-digit HLA alleles in a subset of
UK control subjects separately typed for HLA alleles (Table
S3). We classified RA samples as ACPA on the basis of antiCCP antibody amounts according to standard clinical
practice (see Material and Methods). After adjusting for
ten PCs, we observed little evidence of population stratification (lGC ¼ 0.98, see Material and Methods).
Correcting for Clinical Heterogeneity in ACPA RA
Collections
We considered that other syndromes clinically indistinguishable from ACPA RA might be embedded within
ACPA RA and thus confound associations. Indeed, in an
analysis unadjusted for clinical heterogeneity, we observed
that as we defined ACPA samples by increasing the level
of stringency of the anti-CCP cutoff, the frequency of
HLA-DRb1 Val11 (the strongest risk factor for ACPAþ disease) decreased in our ACPA cohort (p ¼ 6.9 3 105), suggesting confounding from ACPAþ RA (Figure S1). We also
noticed significant association at HLA-B*27 (p ¼ 2.8 3
109), a well-known risk factor for AS,12,21,22 but not at
HLA-C*06:02 (p > 0.001), a risk factor for psoriatic
arthritis.23–25 However, as in most clinical settings, the
phenotypic information that would be essential for identifying and excluding the specific individuals with conditions other than ACPA RA was not available.
To correct for the effects of heterogeneous samples within
our ACPA cohort, we applied a statistical approach to adjust

for confounding diseases (ACPAþ RA and AS, Material and
Methods). We constructed GRSs representing the log OR
for an individual for the confounding disease on the basis
of the known-risk-allele dosages weighted by effect
sizes.26–28 Then, adjusting association statistics in a logistic
regression model for GRSs could successfully control for
the effects of confounding diseases (see Appendix A).
ACPA RA Is Associated with Ser11 and Leu11 in
HLA-DRb1 and Asp9 in HLA-B
After correcting for clinical heterogeneity as described above,
we tested for allelic associations in ACPA RA. Taking into account multiple hypothesis testing, we considered p < 5.6 3
106 (0.05/8,961 binary MHC-marker association tests) to be
significant. After testing all amino acids and classical and
SNP alleles, we observed that the strongest association was
at amino acid residues at position 11 in HLA-DRb1 (presence
of Ser or Leu, OR ¼ 1.30, p ¼ 1.4 3 1013), encoded by HLADRB1 (see Figure 1A, Table 1, and Figure S2). This allele exceeded the significance of all other SNPs and classical alleles
that we tested. The variation of amino acid residues at this
position was attributable to a triallelic SNP (rs9269955,
G/C/A) and a quadallelic SNP (rs17878703) at the first and
second base positions of the codon, respectively. The association at position 11 was statistically indistinguishable (p >
0.09) from the association at position 13 (presence of
Ser, Gly, or Phe, OR ¼ 1.29, p ¼ 4.7 3 1013). The most
strongly associated classical allele was HLA-DRB1*03 (p ¼
6.7 3 1010).13,14 After conditioning on HLA-DRB1*03, we
observed that Ser11þLeu11 remained highly significant
(p ¼ 2.4 3 108), suggesting that HLA-DRB1*03 does not
fully explain HLA-DRB1 associations. We also observed a
separate, strong association 23 kb away from HLA-B at SNP
rs9266669 (OR ¼ 1.38, p ¼ 4.0 3 1013; Figure 1A). This
SNP was statistically indistinguishable (p > 0.01) from the
presence of Asp9 in HLA-B (OR ¼ 1.39, p ¼ 2.7 3 1012);
these two alleles were in tight LD (r2 ¼ 0.8). HLA-B Asp9
was almost perfectly correlated with HLA-B*08 in our data
set (r2 ¼ 0.997). The HLA-B*08 classical allele, Asp9, and
SNP rs9266669 thus could not be distinguished on the basis
of genetics alone. Both of these amino acid sites mapped to
the binding grooves of their respective HLA receptors
(Figure 2).
The HLA-DRB1 and HLA-B associations were independent of each other and explained most of the MHC association with ACPA RA. After conditioning on Ser11þLeu11
effects in HLA-DRb1, we observed that rs9266669 in HLA-B
(or Asp9 in HLA-B) remained the most significant association (p ¼ 2.0 3 107, OR ¼ 1.27; Figure 1B). Similarly, we
observed that after conditioning on Asp9 in HLA-B,
Ser11þLeu11 in HLA-DRb1 remained the most significant
association (p ¼ 1.0 3 107, OR ¼ 1.22; Figure 1C). When
we conditioned on both Ser11þLeu11 in HLA-DRb1 and
Asp9 in HLA-B, no further significant association was
found (p > 0.0007; Figure 1D).
Because the so-called 8.1 ancestral haplotype29 harbors
both HLA-DRb1 Ser11 and HLA-B Asp9, we considered
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Figure 1. Association Results within the
MHC to ACPA RA
(A) We observed the most significant
association at position 11 of HLA-DRb1
(encoded by HLA-DRB1), where Ser and
Leu conferred risk (red diamond). We
also observed an independent association at SNP rs9266669, which was statistically indistinguishable from HLA-B Asp9
(green diamond). The dark-red and darkgreen squares denote the statistical significance of the two positions in a joint
analysis including both discovery and
replication data.
(B) Conditioning on HLA-DRb1 Ser11þ
Leu11, we found that the association at
rs9266669 remained the most significant.
(C) Conditioning on HLA-B Asp9, we
found that the association at HLADRb1 Ser11þLeu11 remained the most
significant.
(D) Conditioning on both HLA-DRb1
Ser11þLeu11 and HLA-B Asp9, we did
not observe any more statistically significant association within MHC (p > 0.0007).

the possibility that these associations were driven by that
haplotype alone and not the individual amino acid sites.
Given that our imputation provided phased haplotypes
spanning the whole MHC region, we inferred the ancestral
haplotype dosage for each individual. Then, using a trivariate logistic regression model including dosages for the 8.1
ancestral haplotype, HLA-DRb1 Ser11þLeu11, and HLA-B
Asp9, we observed that association at the ancestral haplotype was not significant (p ¼ 0.21). In contrast, the other
two HLA amino acid variables retained statistical significance even after adjustment for the effect of the 8.1 ancestral haplotype (p ¼ 1.6 3 107 at HLA-DRb1 Ser11þLeu11
and p ¼ 3.4 3 103 at HLA-B Asp9). These results suggest
that the association was driven primarily by the amino
acid sites and not by the effect of the 8.1 haplotype alone.
We further considered that our approach to correcting
for heterogeneity might be conservative and might remove

shared loci between two subtypes of
RA. To address this concern, we developed a two-step alternative approach
that estimates the confounding proportion (proportion of misdiagnosed
ACPAþ RA samples within ACPA
RA cohorts) by using a GRS calculated
on the basis of an approximated set of
nonshared loci (i.e., known loci associated with ACPAþ RA but with p >
0.01 association in ACPA RA) and
then regresses out only this amount
from the model (see Material and
Methods). The confounding proportion estimates by this approach were
comparable to the estimates by the
previous approach with the full GRS
(mean proportion across cohorts was 26.3% with the full
GRS and 28.3% with the nonshared-loci GRS; see Figure S3). Consistent with the previous approach, this twostep approach produced the most significant associations
at rs9266669 (p ¼ 1.8 3 1013, OR ¼ 1.38 at HLA-B
Asp9) and HLA-DRb1 Ser11þLeu11 (p ¼ 2.3 3 1013,
OR ¼ 1.27). Again, these two associations were independent (p ¼ 5.4 3 108).
Replicating HLA Associations in a Clinically
Homogeneous ACPA Collection
We wanted to validate these findings in an independent
cohort without significant clinical heterogeneity. To this
end, we assessed association in an independent data set
of 427 phenotypically homogeneous ACPA individuals
and 1,691 control subjects (Swedish EIRA). According to
a state-of-the-art commercially unavailable assay,8 these
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Table 1.

Effect Estimates for Amino Acids Associated with Risk of ACPA and ACPAþ RA
OR after Adjustment for Known Associated Positions
(95% CI)

RA
HLA
Subtypes Protein
ACPA

þ

ACPA

Amino Acid Amino Acid
Discovery
Position
Residue

Replication

Joint

Frequency in
Frequency in
Control Group Case Group Classical Alleles

HLA-DRb1 11

SerþLeu

1.22 (1.14–1.32) 1.22 (1.04–1.43) 1.22 (1.14–1.31) 0.514

0.548

HLA-*01, HLA-*03,
HLA-*08, HLA-*11,
HLA-*12, HLA-*13,
HLA-*14

HLA-B

9

Asp

1.27 (1.15–1.40) 1.23 (0.99–1.52) 1.26 (1.15–1.38) 0.131

0.161

HLA-*08

HLA-A

77

Asn

0.85 (0.81–0.90)

0.279

HLA-*01,
HLA-*24,
HLA-*29,
HLA-*36,

0.343

HLA-*23,
HLA-*26,
HLA-*30,
HLA-*80

For each amino acid identified in this study, we show the OR and 95% confidence interval (95% CI), unadjusted frequencies in the case and control groups, and
corresponding classical HLA alleles. All ORs were conditioned on known associated positions; for ACPA RA, we estimated ORs of HLA-DRb1 Ser11þLeu11 and
HLA-B Asp9 by conditioning on each other. For ACPAþ RA, we estimated the OR of HLA-A Asn77 by conditioning on all alleles at HLA-DRB1, amino acids at
HLA-B position 9, and amino acids at HLA-DPb1 position 9. See Table S7 for the complete table, including previously identified positions.

ACPA individuals were negative for not only anti-CCP
antibody but also antibodies for four specific citrullinated
peptide antigens. We also excluded HLA-B*27-positive individuals (>90% sensitive for AS) from case and control
groups. We tested for association without any adjustment
for heterogeneity. We confirmed associations both at
HLA-DRb1 Ser11þLeu11 (p ¼ 5.8 3 104, OR ¼ 1.28)
and at HLA-B Asp9 (p ¼ 2.6 3 103, OR ¼ 1.34) with comparable effect sizes (Table 1). These associations were again
independent of each other. Conditioning on HLA-DRb1
Ser11þLeu11, we observed an independent effect at HLAB Asp9 (p ¼ 0.03, OR ¼ 1.23). Conversely, conditioning
on HLA-B Asp9, we observed an independent effect at
HLA-DRb1 Ser11þLeu11 (p ¼ 0.007, OR ¼ 1.22).
In a joint analysis of the discovery and replication
cohorts, we observed increased significance at both HLADRb1 and HLA-B positions (p ¼ 6.7 3 1016 and OR ¼
1.30 for HLA-DRb1 Ser11þLeu11; p ¼ 5.3 3 1014 and
OR ¼ 1.38 for HLA-B Asp9; Figure 1A and Table S4) and
that their effects were independent (p < 2 3 108; Figures
1B and 1C and Table S4). Conditioning on both of these
effects, we observed no other independent association
throughout the MHC (p > 0.0002).
Exhaustive Search Confirms Associations with Ser11
and Leu11 in HLA-DRb1 and Asp9 in HLA-B
Because the conditional forward search might miss the best
explanations, we exhaustively tested every possible pair of
binary markers in HLA-DRB1 and HLA-B in a joint analysis.
Out of 383,130 pairs we tested, HLA-DRb1 Ser11þLeu11
and HLA-B Asp9 in HLA-B (or equivalently HLA-B*08 and
HLA-B*0801) constituted the most significant pair (p ¼
1.1 3 1020; Table S5), confirming that our model provides
the most parsimonious explanation of the data.
Associations Are Independent of Rheumatoid Factor
Status
We examined whether the associations we identified were
independent of rheumatoid factor (RF) status. We obtained

RF data for 1,016 affected individuals in the UK cohort; 470
individuals (46%) were RFþ, and 546 individuals (54%)
were RF. We stratified the samples into two groups on
the basis of RF status. The associations were consistent between the two groups in that they showed the same direction of effects at both HLA-DRb1 Ser11þLeu11 and HLA-B
Asp9 (Table S6). We observed that effect sizes tended to be
greater in the RFþ subjects than in the RF subjects at both
loci (p ¼ 0.02). A thorough investigation of this phenomenon will require larger sample sizes.
Asn77 at HLA-A Is Associated with ACPAþ RA
We also mapped associations within the MHC to ACPAþ
RA in 7,279 ACPAþ RA subjects and 15,870 control subjects
(see Table S1 and Material and Methods). We observed little
evidence of stratification after adjusting for ten PCs (lGC ¼
1.07). We confirmed previously published associations in
HLA-DRb1 at amino acid positions 11 (p < 10692), 71
(p < 1037), and 74 (p < 1023) (Table S7). Conditioning
on HLA-DRB1 alleles, we confirmed associations at Asp9
in HLA-B (p < 1036, OR ¼ 1.93) and Phe9 in HLA-DPb1
(p < 1019, OR ¼ 1.31)6 (Figure S4). Conditioning on all
of these previously known associated positions (the HLADRB1 alleles, position 9 in HLA-B, and position 9 in HLADPb1), we observed an independent association with
ACPAþ RA with the presence of Asn77 in HLA-A (p ¼
2.7 3 108, OR ¼ 0.85; Figure S4D and Table 1). Similar
to the other amino acid sites associated with RA,6 position
77 in HLA-A was also located in the binding groove
(Figure 2 and Figure S5). We previously observed that
Ser77 in HLA-A confers protection in HIV controllers.31
After conditioning on this sixth position, we observed no
convincing associations (p > 4 3 106).

Discussion
In this study, we observed that associations with ACPA RA
within the MHC were driven by HLA-DRB1 and HLA-B. In
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Figure 2. 3D Models of Amino Acid Positions Identified in This Study
Key amino acid positions are highlighted
as spheres. We used Protein Data Bank entries 3pdo (HLA-DR), 2bvp (HLA-B), and
1x7q (HLA-A) with UCSF Chimera to prepare the figure.30 See Figure S5 for all
known associated positions.

addition, we identified the specific residues and specific
amino acid sites that parsimoniously explained these associations. These positions mapped to the peptide binding
grooves of these receptors, pointing to an important role
for antigen recognition. The success of this study was
contingent on our ability to distinguish the effects from
other conditions contributing to heterogeneity within
the case individuals.
Intriguingly, the positions that drove ACPA risk were
the same positions that drove most risk for ACPAþ RA as
well (Table S8). The risk of Asp9 in HLA-B in ACPA RA
was shared with ACPAþ disease but had a more modest
effect size (OR ¼ 1.38 in ACPA versus OR ¼ 1.93 in
ACPAþ). This allele, also associated with myasthenia
gravis,32 might affect nonspecific immune reactivity.
In contrast, at position 11 of HLA-DRb1, different residues drove risk of the two diseases (discordance p <
2.9 3 10107; Figure 3). For example, Ser11 conferred risk
of ACPA disease (OR ¼ 1.31) but was protective against
ACPAþ disease (OR ¼ 0.39). On the other hand, Gly11
and Pro11 showed protective effects for both subsets. We
speculate that citrullinated antigens that drive ACPAþ RA
risk might be biochemically distinct from the antigens
driving ACPA RA risk, for example, carbamylated antigens.33 The different set of risk and protective residues
for the two disease subsets might be related to differential
binding affinity and reactivity to these autoantigens.
In a multicohort study where allele frequencies can
differ between cohorts, it is crucial to account for population stratification. For example, the frequency of ancestral
8.1 haplotype differed from 5% to 17% depending on
cohorts (Table S9). As described in the Material and
Methods, we took two approaches to account for population structure: (1) we stratified the data by country of
origin, and (2) we used ten PCs to aggressively adjust for
any residual population effects. The effectiveness of this
standard approach is reflected in the relatively modest
inflation factors for the study (l1,000 ¼ 1.00 for ACPA
RA and l1,000 ¼ 1.01 for ACPAþ RA).
In this study, we addressed the issue of heterogeneity
within cohorts. Like for population stratification, if the
heterogeneity is present and we fail to adequately adjust
for it, spurious associations can occur. For example,
without adjusting for heterogeneity, the top ACPA RA
association appeared to be at Leu67 in HLA-DRb1 (p ¼
2.9 3 1028). Despite its remarkable significance in our het-

erogeneous discovery sample, Leu67 failed to replicate
when we examined it in our homogenous replication
data set (p ¼ 0.26). In contrast, after adjusting for heterogeneity in our discovery data set, we observed the strongest
effect at position 11 of HLA-DRb1 (Table 1); not only did
this effect replicate in our homogenous replication data
set, but the effect sizes of each amino acid residue at that
site were also highly concordant between discovery and
replication sets (discordance p > 0.4 after adjustment;
Figure S6).
To further demonstrate the potential for accounting for
heterogeneity in fine mapping, we performed simulations.
We simulated a study under the assumption that HLADRb1 Ser11þLeu11 (OR ¼ 1.30) and HLA-B Asp9 (OR ¼
1.39) confer risk, which is the model that we found in
this study, and included ACPAþ RA subjects in 26.3% of
affected individuals (Material and Methods). Without
adjustment for heterogeneity, the top association was
deceivingly at HLA-DRb1 Leu67 (p < 10331), which was
exactly what we observed in discovery cohorts without
adjusting for heterogeneity. Using our statistical approach
to adjust for heterogeneity, we were able to map the correct
positions we simulated; the top associations were HLADRb1 Ser11þLeu11 (p ¼ 1.3 3 10189), and conditioned
on this, rs2853986 (p ¼ 7.2 3 1059), which was statistically indistinguishable (p > 0.05) from HLA-B Asp9. We
also showed that adjusting for heterogeneity not only
removed spurious associations but also provided accurate
estimation of the proportion of confounding samples
under the null model (Figure S7).
We note that we adjusted for possible confounding from
AS by correcting for AS GRSs in discovery cohorts and
removing HLA-B*27-positive individuals in the replication
cohort. This approach effectively adjusted for putative
HLA-B*27 associations with ACPA RA if there were any.
Currently, it is difficult to distinguish true HLA-B*27 associations from confounding from AS. We expect that we will
be able to accurately distinguish these two situations as we
identify a greater number of non-MHC AS risk loci in the
future.
The concern of clinical heterogeneity extends beyond
RA to a wide range of diseases where clinical classification
might be uncertain because of imperfect diagnostic tests,
for example, (1) subclassification of inflammatory bowel
disease (MIM 266600) into Crohn disease or ulcerative
colitis or (2) distinguishing early bipolar disease (MIM
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role of genetic data in helping categorize individuals with
ACPA inflammatory arthritis.

Appendix A

Figure 3. Distinct Effect Sizes of Amino Acid Residues at HLADRb1 Position 11 for ACPA and ACPAþ RA
For each residue, we show the univariate OR (OR with respect to
the other residues as a reference) and the 95% confidence interval.
Effect sizes were distinct between the two disease subsets (p <
2.9 3 10107).

125480) from major depressive disorder (MIM 608516).
We expect that our statistical approach might have
application to genetic studies of these conditions as well.
The applicability of our approach is contingent on
adequate power to detect confounding genetic effects;
such power is only possible when sufficient numbers of genetic loci for confounding diseases are known. We also
expect that our approach might have utility in better characterizing non-HLA loci of the conditions with clinical
heterogeneity.
Our results have important implications for the clinical
practice of ACPA RA. Investigators have long speculated
that individuals diagnosed with ACPA RA might have
other inflammatory arthritic conditions, such as AS, that
mimic RA and have atypical clinical presentations. Our
analysis supports this; we estimated here that each
ACPA RA cohort contained 4%–11% of the affected individuals who most likely had AS and 15%–37% of affected
individuals who most likely had ACPAþ RA (Table S10
and Figure S3). We note the possibility that other conditions that we did not account for, such as Sjögren syndrome (MIM 270150),34 might have been included within
the ACPA RA samples. These subjects were identified
through research protocols, and in clinical practice, these
diagnostic uncertainties can be even more pronounced.
Clinical misclassifications can be particularly concerning
in this setting given that optimal pharmacological treatment and long-term prognosis for these different arthritic
conditions vary. Our data not only underscore the need for
more accurate clinical tests than the conventional antiCCP antibody testing but also illuminate the potential

Asymptotic Mean of Effect-Size Estimate in the
Presence of Confounding
We first consider linear regression for quantitative traits.
We assume a single locus, which we will extend to multiple
loci later. Suppose that two groups of samples are mixed in
a cohort. Let x1 and x2 be the genotype vectors of the two
groups at the locus and y1 and y2 be the phenotype vectors.
Let b1 and b2 be the effect sizes, such that the true model is
y1 ¼ x1 b1 þ ε1 and y2 ¼ x2 b2 þ ε2 , where ε1 and ε2 are error
terms. Without loss of generality, assume that x1, x2, y1,
and y2 have zero mean. Because of sample mixture, what
we observe are x ¼ ðxT1 jxT2 ÞT and y ¼ ðy1T jy2T ÞT . The standard
linear regression formula gives us the least-squares estimate of effect size:

1
b
b ¼ xT x xT y
T

1  T T 
¼ xT1 x1 þ xT2 x2
x1 j x2 ðx1 b1 þ ε1 ÞT j ðx2 b2 þ ε2 ÞT
1  T
 


x1 x1 b1 þ xT1 ε1 þ xT2 x2 b2 þ xT2 ε2
¼ xT1 x1 þ xT2 x2



1  T 
1
¼ xT1 x1 þ xT2 x2
x1 x1 b1 þ xT1 x1 xT1 ε1


1


þ xT2 x2 b2 þ xT2 x2 xT2 ε2
Given that E½ðxT1 x1 Þ1 xT1 ε1  ¼ 0 and E½ðxT2 x2 Þ1 xT2 ε2  ¼ 0,
h i 
1  T

E b
b ¼ xT1 x1 þ xT2 x2
x1 x1 b1 þ xT2 x2 b2
If we assume that the minor allele frequency of the
variant is the same for the two groups and the genotypes
follow Hardy-Weinberg equilibrium, ðxT1 x1 Þ=ðxT2 x2 ÞzN1 =
N2 , where N1 and N2 are the sample sizes of the two groups.
Thus, the effect-size estimate asymptotically converges to
an average effect size weighted by the sample sizes of two
groups.
This result has the following implication. Suppose that b1
is the true effect size of interest and b2 is the effect size for
confounding samples. Consider the null model (b1 ¼ 0).
What we observe will be E½ b
b ¼ ab2 , where a is the confounding proportion. Thus, we will have spurious association ðE½ b
bs0Þ. Suppose that we build GRSs with respect to
confounding disease as s ¼ xb2 . If we regress out s as a covariate, it will remove spurious association. Moreover, the
regression coefficient of s will be an unbiased estimator of a.
Under the alternative model ðb1 s0Þ, using risk score as a
covariate might be conservative and remove true association. If we know a a priori, one approach is fixing the coefficient of s to the constant a. That is, we subtract sa ¼ xb2 a
from y. This approach will retain true association. The
effect-size estimate can still be conservative, given that
what we would want to subtract is actually xðb2  b1 Þa,
which is unknown.
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Logistic Regression
Similar results extend to logistic regression. For simplicity,
we assume the null model (true OR is 1). Suppose that a%
of the case group is confounded by a disease whose OR is
gs1. Let p be the control minor allele frequency. Then,
the asymptotic mean of the observed log OR b
b will be
h i
b ¼ p ¼ log
E b

ðapA þ ð1  aÞpÞð1  pÞ
;
ðað1  pA Þ þ ð1  aÞð1  pÞÞp

where pA ¼ gp=ððg  1Þp þ 1Þ is the case minor allele frequency of the confounding disease. Thus, we will have
spurious association ðE½ b
bs0Þ.
If g is small, we can establish an approximate relationship, pzalogðgÞ, which we show by simulations (Figure S8). Thus, using risk score s ¼ logðgÞx as a covariate,
we can not only remove spurious association but also
approximate a from the regression coefficient of s.
Generalization to Multiple Loci
We can generalize our approach to multiple loci. Suppose
that we know m independent loci associated with the confounding disease. Let b1 ; .; bm be their effect sizes. We
build GRSs for each individual locus,
si ¼ xi bi

i˛f1; :::; mg;

where xi is the genotype vector at locus i. In order to estimate the confounding proportion a, we look at all loci
together by including all si in the regression:
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y ¼ as1 þ as2 þ . þ asm þ ε:
Application to logistic regression is also straightforward.
Because a is invariant across loci, this is equivalent to
the model using a combined GRS, y ¼ aS þ ε, where
P
P
S ¼ si ¼ xi bi , which results in the approach presented
in the Material and Methods. The advantage of a combined
GRS over multiple loci is that it can be less conservative
under the alternative model. For example, if we test locus
i and include si as a covariate, it will remove true association. However, if we include S as a covariate, the information from other loci ðs1 ; s2 ; .; si1 ; siþ1 ; .; sm Þ will help in
finding correct a and preventing overly regressing out si.
Another possible way to more strictly prevent overly regressing out GRS can be estimating a with nonoverlapping
loci first, as presented in the Material and Methods.
Supplemental Data
Supplemental Data include eight figures and ten tables and can be
found with this article online at http://www.cell.com/ajhg.
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